An updated patent review of small-molecule ROS1 kinase inhibitors (2015-2021) [0.03%]
2015-2021年上市ROS1小分子激酶抑制剂专利回顾及分析
Meng Liu,Jintian Dai,Mudan Wei et al.
Meng Liu et al.
Introduction: C-ros oncogene 1 (ROS1) is the sole member of the ROS1 receptor tyrosine kinase (ROS1-RTK) family, which is involved in the formation of non-small cell lung cancer (NSCLC), gastric adenocarcinoma, colorectal...
A patent review of ubiquitin-specific protease 7 (USP7) inhibitors (2014-present) [0.03%]
2014年以来泛素特异性蛋白酶7（USP7）抑制剂专利分析评论
Peng Li,Ying Liu,Hong-Min Liu
Peng Li
Introduction: Ubiquitin-specific protease 7 (USP7) plays a critical role in multiple signaling pathways, and many recent studies have proved its association with many diseases. The USP7-murine double minute 2-p53 pathway ...
Nucleotide pyrophosphatase/phosphodiesterases (NPPs) including NPP1 and NPP2/ ATX as important drug targets: A patent review (2015-2020) [0.03%]
核苷酸焦磷酸酶/磷二酯酶(NPP)，包括NPP1和NPP2/ATX的重要药物作用靶点：2015—2020年专利回顾
Sehrish Bano,Mariya Al-Rashida,Rima D Alharthy et al.
Sehrish Bano et al.
Introduction: Ectobucleotidases are a broad class of extracellular nucleotide and nucleoside hydrolyzing enzymes. Since they play a crucial role in mediating purinergic cell signalling, they are promising therapeutic targ...
Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present) [0.03%]
新的STAT3信号通路抑制剂专利回顾（2014-至今）
Feng Wang,Xin-Yu Cao,Guo-Qiang Lin et al.
Feng Wang et al.
Introduction: STAT3 is a critical transcription factor that transmits signals from the cell surface to the nucleus, thus influencing the transcriptional regulation of some oncogenes. The inhibition of the activation of ST...
Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019-2021) [0.03%]
程序性细胞死亡配体1(PD-L1)的小分子抑制剂专利回顾(2019-2021)
Jingjing Deng,Zhengqi Cheng,Juyang Long et al.
Jingjing Deng et al.
Introduction: The blockade of immune checkpoints, especially the PD-1/PD-L1 pathway with therapeutic antibodies, has shown success in treating cancers in recent years. Seven monoclonal antibodies (mAbs) targeting PD-1 or ...
Sara Consalvi,Chiara Tammaro,Federico Appetecchia et al.
Sara Consalvi et al.
Introduction: Despite substantial progress in the field, malaria remains a global health issue and currently available control strategies are not sufficient to achieve eradication. Agents able to prevent transmission are ...
Rita Maria Concetta Di Martino,Andrea Cavalli,Giovanni Bottegoni
Rita Maria Concetta Di Martino
Introduction: Compelling evidence identified D3 dopamine receptor (D3R) as a suitable target for therapeutic intervention on CNS-associated disorders, cancer, and other conditions. Several efforts have been made toward de...
Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021 [0.03%]
作为莱什曼病小分子纤毛虫特异性蛋白酶体抑制剂的专利回顾（1998-2021）
Mohd Imran,Shah Alam Khan,Abida et al.
Mohd Imran et al.
Introduction: Leishmaniasis is a neglected tropical infectious disease. The available limited therapeutic options for leishmaniasis are inadequate due to their poor pharmacokinetic profile, resistance, toxicity, high cost...
Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021) [0.03%]
menin-MLL蛋白-蛋白相互作用抑制剂专利综述(2014-2021)
Huanrong Bai,San-Qi Zhang,Hao Lei et al.
Huanrong Bai et al.
Introduction: Chromosomal translocations involving the mixed-lineage leukemia (MLL, KMT2A, MLL1) genes result in the production of MLL fusion proteins, which cause abnormal transcriptional regulation leading to acute leuk...
A patent review on cathepsin K inhibitors to treat osteoporosis (2011 - 2021) [0.03%]
2011-2021年关于猫酸酶K抑制剂治疗骨质疏松症的专利分析
Fernanda R Rocho,Vinícius Bonatto,Rafael F Lameiro et al.
Fernanda R Rocho et al.
Introduction: Cathepsin K (CatK) is a lysosomal cysteine protease and the predominant cathepsin expressed in osteoclasts, where it degrades the bone matrix. Hence, CatK is an attractive therapeutic target related to disea...